Status:
UNKNOWN
Prevention of Graft Reinfection After Liver Transplantation With Anti HCV Monoclonal Antibodies Identified in Chronically Infected Patients or in Patients With Resolved Hepatitis C
Lead Sponsor:
University Hospital, Strasbourg, France
Conditions:
Hepatitis C
Eligibility:
All Genders
18-75 years
Brief Summary
End stage HCV-related cirrhosis has become a major indication for liver transplantation (LT). Unfortunately, recurrence of HCV infection on the liver graft occurs in almost all patients following tran...
Eligibility Criteria
Inclusion
- Health insurance
- Resolved HCV infection ( HCV RNA negative since more then 6 months ) -HCV chronically infected ( RNA positive )
- Anti- HCV antibodies positive
- Volunteers and informed patients
Exclusion
- Immunosuppression
- HBV or HIV infection
- Pregnancy
- Breast feeding
Key Trial Info
Start Date :
February 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2015
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT00638144
Start Date
February 1 2008
End Date
December 1 2015
Last Update
September 30 2015
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Service d'Hépato-Gastro-Entérologie - Hôpital Civil
Strasbourg, France, 67000
2
Service d'Hématologie et Oncologie - Hôpital de Hautepierre
Strasbourg, France
3
Service de Chirurgie Générale et Transplantation Multiorganes - Hôpital de Hautepierre
Strasbourg, France